MedTrace Logo

Patterns of Prescribing and Monitoring of Palbociclib

NCT03285568 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 67

Last updated 2023-03-31

No results posted yet for this study

Summary

The purpose of this study is to determine if patients with ER+, human epidermal growth factor 2 negative (HER2-), advanced breast cancer are receiving dosing adjustments and monitoring based on manufacturer recommendations at a tertiary academic medical center.

Conditions

Interventions

DRUG

Palbociclib

Observe patients receiving palbociclib for dose adjustment and lab monitoring

Sponsors & Collaborators

  • Rush University Medical Center

    lead OTHER

Principal Investigators

  • Kathryn Schultz · Rush University Medical Center

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-02-03
Primary Completion
2016-12-30
Completion
2016-12-30
FDA Drug
Yes

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03285568 on ClinicalTrials.gov